Loading...
•
Mar 31, 2021
Baxter Q1 2021 Earnings Report
Reported a 5% increase in first-quarter revenue and a decline in both U.S. GAAP EPS and Adjusted EPS.
Key Takeaways
Baxter International Inc. reported a 5% increase in first-quarter revenue, driven by Acute Therapies and BioPharma Solutions. The company's U.S. GAAP earnings per share (EPS) declined 9%, and adjusted EPS decreased by 7%. Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis.
First-quarter revenue increased 5% on a reported basis.
U.S. GAAP earnings per share (EPS) declined 9%.
Adjusted EPS declined 7%.
Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis.
Baxter
Baxter
Baxter Revenue by Segment
Baxter Revenue by Geographic Location
Revenue by Segment
Pharmaceuticals Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis. The company expects U.S. GAAP earnings of $2.85 to $2.93 per diluted share and adjusted earnings of $3.47 to $3.55 per diluted share.
Positive Outlook
- Full-year 2021 sales growth of 8% to 9% on a reported basis.
- Full-year 2021 sales growth of 5% to 6% on a constant currency basis.
- Full-year 2021 sales growth of 4% to 5% on an operational basis.
- Full-year U.S. GAAP earnings of $2.85 to $2.93 per diluted share.
- Full-year adjusted earnings of $3.47 to $3.55 per diluted share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income